Hoth Therapeutics received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics announces positive data from skin toxicities with HT-001
- Hoth Therapeutics assumed with a Buy at EF Hutton
- Hoth Therapeutics and Aronnax sign master services agreement for HT-KIT
- Biotech Alert: Searches spiking for these stocks today
- Hoth Therapeutics expands Phase 2a of HT-001 trial for skin cancer